根据最新的财务报表(Form-10K),Artius II Acquisition Inc 的总资产为 $0,净损失为 $0
MRES 的关键财务比率是什么?
Artius II Acquisition Inc 的流动比率是 0,净利 margin 为 0,每股销售为 $0。
Institute of Biomedical Research Corp 的收入按细分市场或地理位置如何划分?
Artius II Acquisition Inc 最大收入来源是 Branded Products,在最近的收益报告中收入为 26,000,652。就地区而言, United States 是 Artius II Acquisition Inc 的主要市场,收入为 26,000,652。
Institute of Biomedical Research Corp 是否盈利?
不,根据最新的财务报表,Artius II Acquisition Inc 的净损失为 $0
Institute of Biomedical Research Corp 有负债吗?
不,Artius II Acquisition Inc 的负债为 0
Institute of Biomedical Research Corp 的流通股有多少?
Artius II Acquisition Inc 的总流通股为 5.17
关键数据
前收盘价
$0.0014
开盘价
$0.002
当日区间
$0.002 - $0.002
52周范围
$0.0007 - $0.0241
交易量
940.0K
平均成交量
812.7K
股息收益率
--
每股收益(TTM)
--
市值
$4.7M
什么是 MRES?
Institute of BioMedical Research Corp. engages in research and development, quality control and standardization of pharmaceuticals, cosmetics and food products. The company is headquartered in Niksic, Niksic. The company went IPO on 2000-10-27. The firm's services include scientific research and biomedical services, such as research and development, quality control, standardization of pharmaceuticals, cosmetics and food products. The firm also provides long-term biomedical and environmental research projects, develops new diagnostic biomedical technologies and experimental medical treatments. The firm's products include Aerosan, MicrobEX, Microbicidal Towels KleNET, OralNet, Oral Ocean Power and Purilair. The company offers electro medical devices, such as BioMed 2000 XT with Timer, BioStim INF, QuadStar Elite, QuadStar II, Pain Gone piezo-electric pain relief and Portable Ultra Sound Device. The company offers various services, including quality control services, regulatory services, healthcare services, environmental analyses, building decontamination, and environmental protection and management.